Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with over 270 patents, announced its participation in the 2025 Cell & Gene Meeting on the Mesa Conference. Chief Scientific Officer Dr. Hamid Khoja will present on October 7, 2025, at 2:15 p.m. MST in Phoenix, Arizona.
The company, which specializes in developing therapeutics using fibroblasts and fibroblast-derived materials, plans to initiate a clinical trial for diabetic foot ulcers in Q1 2026. The presentation will provide updates on their fibroblast-based technologies and their potential applications in treating various chronic diseases.
FibroBiologics (NASDAQ: FBLG) has published an opinion editorial highlighting the potential advantages of fibroblast cells over traditional stem cell therapies. The article, authored by CEO Pete O'Heeron and CSO Hamid Khoja, Ph.D., presents research supporting fibroblasts' superior characteristics including faster proliferation rates, better sourcing capabilities, and enhanced immune modulation properties.
The company's research focuses on treating chronic diseases such as multiple sclerosis, rheumatoid arthritis, and wound healing applications. With 270+ issued and pending patents, FibroBiologics positions fibroblast-based solutions as potentially superior to mesenchymal stem cells in terms of clinical utility, safety profile, and scalability.
FibroBiologics (NASDAQ:FBLG) has announced positive IND-enabling updates for its psoriasis treatment program using human dermal fibroblast (HDF) spheroids. The company reported that a single administration of HDF spheroids matched the efficacy of multiple doses of an anti-IL-23 monoclonal antibody in an acute psoriasis model, while also significantly reducing disease recurrence in a chronic-relapse model.
The biotechnology company, which holds over 270 patents issued and pending, is advancing its research through pilot studies focused on repeated dosing regimens, cytokine profiling, and histopathological assessments. The treatment targets psoriasis, an autoimmune condition affecting more than 8 million adults in the United States, with potential to address the broader chronic inflammatory disease market.
FibroBiologics (NASDAQ:FBLG) has announced significant progress in its Bone Marrow Organoid platform technology, showing promising potential for treating hematopoietic cancers and immune-related conditions. The company's pre-IND animal trials demonstrated that transplantation of these organoids significantly reduced tumor size in xenografted melanoma mouse models.
Key technological advantages include efficient ex vivo gene editing capabilities and the ability to cryopreserve the organoids for scalable treatment options. The platform shows potential for regenerating immune cell types, addressing age-related immune decline, and restoring immune function in compromised patients. Additionally, the technology could enable in-vivo generation of advanced cell therapies like CAR-T and CAR-NK cells directly within patients.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focused on developing therapeutics using fibroblasts and fibroblast-derived materials, will participate in the H.C. Wainwright 27th Annual Global Investment Conference.
The company's CEO, Pete O'Heeron, will deliver a presentation on September 10 at 12:00 p.m. ET at the Lotte New York Palace Hotel. The company, which holds over 275 patents issued and pending, will also be available for one-on-one meetings with investors during the conference.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, reported its Q2 2025 financial results and corporate updates. The company secured the third $5 million tranche of a $25 million financing round and appointed Jason D. Davis as CFO. For H1 2025, FibroBiologics reported a net loss of $9.6 million, with cash reserves of $8.8 million as of June 30, 2025.
The company presented promising pre-clinical evidence for fibroblast spheroids in psoriasis treatment and confirmed the use of CYWC628 master cell bank for CybroCell™ manufacturing. Key upcoming milestones include initiating a Phase 1/2 clinical trial for diabetic foot ulcers in Q1 2026 and completing pre-clinical IND-enabling studies for psoriasis treatment by end of 2025.
FibroBiologics (NASDAQ: FBLG) has filed a patent application with the USPTO for methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. The biotechnology company, which holds 275+ patents, focuses on developing therapeutics using fibroblasts and fibroblast-derived materials.
The innovation enables the generation of stable multipotent cells directly from donor-derived fibroblasts, which can differentiate into various cell types including chondrocytes, osteocytes, hepatocytes, and cardiomyocytes. According to Chief Scientific Officer Hamid Khoja, this method allows for obtaining larger quantities of stable and scalable multipotent cells, with enhanced ability to form 3D spheroid structures.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focused on developing fibroblast-based therapeutics, announced its participation in the Advanced Wound Care Summit USA in Boston on July 15, 2025.
CEO Pete O'Heeron will present the company's recent research advances in fibroblast-based technology for wound healing and psoriasis. The presentation will highlight CYWC628 therapy for diabetic foot ulcers, with a Phase 1/2 clinical trial planned to begin later in 2025. The therapy aims to leverage the body's natural regenerative processes rather than just managing symptoms.
FibroBiologics (NASDAQ: FBLG) has achieved a significant milestone in its cartilage repair program by confirming that CYWC628 spheroids from its existing master cell bank can be differentiated into chondrocytes for cartilage formation. This breakthrough enables the company to manufacture CybroCell™, its investigational cell therapy for degenerative disc disease (DDD).
The development allows FibroBiologics to proceed with amending its FDA IND clearance for the planned Phase I clinical trial for DDD. The company's ability to use the existing master cell bank is expected to streamline manufacturing, reduce development time, and lower associated costs. This advancement demonstrates the potential versatility of FibroBiologics' fibroblast-based platform to support multiple therapeutic indications from a common cell source.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company with 275+ patents, will host an exclusive investor webinar on July 10, 2025, at 4:15 p.m. ET. CEO Pete O'Heeron will present the company's innovative fibroblast-based cell therapy platform targeting chronic, inflammatory, and degenerative conditions.
The presentation will highlight their lead candidate CYWC628 for diabetic foot ulcers, along with programs targeting degenerative disc disease and multiple sclerosis. FibroBiologics' approach uses allogeneic fibroblasts to develop scalable, off-the-shelf solutions, leveraging these cells' regenerative and immunomodulatory properties. The webinar will include a Q&A session, and a recording will be available on the company's website.